| Literature DB >> 30459630 |
Ghassen Cheniti1,2,3, Konstantinos Vlachos1,2, Thomas Pambrun1,2, Darren Hooks4, Antonio Frontera1,2, Masateru Takigawa1,2, Felix Bourier1,2, Takeshi Kitamura1,2, Anna Lam1,2, Claire Martin1,2, Carole Dumas-Pommier1, Stephane Puyo2, Xavier Pillois1, Josselin Duchateau1,2, Nicolas Klotz1,2, Arnaud Denis1,2, Nicolas Derval1,2, Pierre Jais1,2, Hubert Cochet2,5, Meleze Hocini1,2, Michel Haissaguerre1,2, Frederic Sacher1,2.
Abstract
AF is a heterogeneous rhythm disorder that is related to a wide spectrum of etiologies and has broad clinical presentations. Mechanisms underlying AF are complex and remain incompletely understood despite extensive research. They associate interactions between triggers, substrate and modulators including ionic and anatomic remodeling, genetic predisposition and neuro-humoral contributors. The pulmonary veins play a key role in the pathogenesis of AF and their isolation is associated to high rates of AF freedom in patients with paroxysmal AF. However, ablation of persistent AF remains less effective, mainly limited by the difficulty to identify the sources sustaining AF. Many theories were advanced to explain the perpetuation of this form of AF, ranging from a single localized focal and reentrant source to diffuse bi-atrial multiple wavelets. Translating these mechanisms to the clinical practice remains challenging and limited by the spatio-temporal resolution of the mapping techniques. AF is driven by focal or reentrant activities that are initially clustered in a relatively limited atrial surface then disseminate everywhere in both atria. Evidence for structural remodeling, mainly represented by atrial fibrosis suggests that reentrant activities using anatomical substrate are the key mechanism sustaining AF. These reentries can be endocardial, epicardial, and intramural which makes them less accessible for mapping and for ablation. Subsequently, early interventions before irreversible remodeling are of major importance. Circumferential pulmonary vein isolation remains the cornerstone of the treatment of AF, regardless of the AF form and of the AF duration. No ablation strategy consistently demonstrated superiority to pulmonary vein isolation in preventing long term recurrences of atrial arrhythmias. Further research that allows accurate identification of the mechanisms underlying AF and efficient ablation should improve the results of PsAF ablation.Entities:
Keywords: atrial fibrillation; catheter ablation; fibrosis; mapping; pulmonary vein ablation; reentrant drivers
Year: 2018 PMID: 30459630 PMCID: PMC6232922 DOI: 10.3389/fphys.2018.01458
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1Coumel triangle summarizing the different contributors to AF.
Figure 2Schematic representation of the mechanisms maintaining AF. (A) Single stable focal or reentrant source (star) with fibrillatory conduction. (B) Multiple wavelets: multiple waves propagate randomly and give birth to new daughter wavelets. (C) Multiple reentries (red arrows) around areas of scar and fibrosis. (D) Combination of the different mechanisms that sustain AF in humans. These mechanisms are typically meandering and last for few consecutive beats.
Figure 4Phase maps acquired during AF in patients with PAF (A), PsAF of 4 months (B) and long lasting PsAF >12 months (C). Red spots identify sites of phase singularity.
Figure 5Unipolar signals recorded during a one second window of AF. Electrograms at the site of reentrant activities (red spots) show a complex and turbulent activity while the activity in the remaining atria is homogeneous. A reentry can be identified by analyzing the surrounding electrograms (white arrows) that show a sequential temporal activation. LA, left atrium; LAA, left atrial appendage; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein; RA, right atrium; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein.
Summary of the different approaches of percutaneous ablation of AF.
| Haïssaguerre et al., | 45 PAF | Earliest site of activation of the ectopic beat initiating AF | 69 ectopic sites, 94% originating from the PV | 62% AF freedom after 8 ± 6months |
| Chen et al., | 79 PAF | Earliest site of activation of the ectopic beat initiating AF | 116 ectopic foci, 88.8% originating from the PV | 86% AF freedom after 6 ± 2 months, Focal stenosis in 42.4% of the PVs |
| Haissaguerre et al., | 70 PAF | PV isolation (except RIPV) by targeting atrial breakthroughs | 73% AF freedom after 4± 5 months, (29 patients had re-ablation session) | |
| Deisenhofer et al., | • 69 PAF | Segmental PVI | PVI achieved in 89% of the veins | 51% AF freedom after 230 ± 133 days |
| Arentz et al., | • 37 PAF | Segmental PVI | PVI achieved in 99% of the veins | 27 pts underwent a second procedure |
| SMART AF | • 172 PAF | • 160 PVI using contact force sensing catheter | • Atrial arrhythmia freedom after 1-year follow-up | |
| STAR-AF study | 589 PsAF | 67: CPVI, | CPVI + CFAE and CPVI + lines were not superior to CPVI alone after 18% follow-up (AF freedom = 49,46, 59% respectively, | |
| CHASE-AF trial | 153 PsAF | 78 pts PVI alone, | • PVI group: SR achieved with electrical cardioversion | No difference in the AF freedom after 1-year follow-up: 61.4% in the PVI group, vs. 58.3% in the full-defrag group |
| FIRE AND ICE trial | 762 PAF | • 378: PVI using cryoablation | • Successful PVI | • AF and AT freedom without anti-arrhythmic drugs after a mean of 1.5-year follow-up was not different between the two groups: |
| Alster-Lost-AF Trial | • 69 PsAF 6- 12 months | • 61 pts CPVI-only | • AF termination | • AF freedom after 1 year follow-up and a single procedure without AAD: |
| CASTLE AF trial | • 363 pts NYHA II,III,IV with PAF or PsAF, LVEF ≤35% and an ICD | • Ablation = 179 pts vs. medical therapy = 184 | • Ablation significantly reduced death from any cause and hospitalizations for worsening heart failure | |
| TIlz et al., | 161 PAF | CPVI using EAM and double-Lasso technique | • All PVI were isolated during the index procedure | • 10-year AF freedom |
| Nademanee et al., | • 57 PAF | CFAE ablation | Acute termination without antiarrhythmic drugs | • AF freedom after 1 procedure at 1year follow-up = 76% |
| Oral et al., | 100 PsAF | CFAE ablation | Acute termination without antiarrhythmic drug: 16% | • AF freedom after 14 ± 7 months = 33% |
| Oral et al., | 119 long lasting PsAF | • 19 PVI | • AF termination by PVI only = 16% | AF freedom after 1 procedure: 36% in the absence of CFAE ablation and 34% after CFAE ablation (P = NS) No benefit of additional CFAE ablation |
| SELECT-AF study | • 48 PsAF | • 38 pts: CPVI and all CFAE | • CFAE ablation prolonged AF cycle length and resulted in similar rates of | AF, AFL and AT freedom without anti-arrhythmic drugs after 1-year follow-up significantly lower after selective CFAE ablation (28% vs.50%) |
| Atienza et al., | • PAF = 115, AF induced in 95 pts | • PAF = CPVI or high frequency sources ablation (HFSA) | • AF termination | • AF/AT freedom after 1 year-follow-up after a single procedure |
| Faustino et al., | PAF: 150 | • 75 PVI alone | • AF termination and non-inducibility achieved in 100% of the stepwise approach | • AF freedom after a first procedure at 1-year follow up significantly higher in the stepwise group: |
| Seitz et al., | 33 PAF | • 105 = ablation only regions displaying electrogram dispersion during AF | • Ablation only at dispersion areas terminated AF in 95% of the pts. | • AF freedom after a mean of 1.5 procedures per patient procedures after 18 month-follow-up: |
| Cuculich et al., | • PAF: 11 | Driver domains identified by ECGi | • Multiple wavelets: most common pattern (92% of the patients) | N/A |
| Haissaguerre et al., | • PsAF in SR = 26 | Driver domains identified by ECGi | 80% AF termination after 28 ± minutes of RF ablation. AF complexity increased with AF duration | 85% AF freedom at 12 months in group, no difference compared to the control group |
| Lim et al., | • PsAF in SR = 32 | Driver domains identified by ECGi | • 70% AF termination, | NA |
| Knecht et al., | • PsAF in SR = 32 | Driver domains identified by ECGi in 8 different centers | 64% AF termination after 46 ± 28min RF ablation | • AF freedom after 1-year follow-up was 77% |
| Narayan et al., | • PAF = 31 | FIRM guided: | FIRM guided AF termination in 56% of the cases vs. 9% with conventional ablation | 82% in the FIRM guided ablation vs. 45% AF freedom after 9 months |
| Pappone et al., | PsAF: 81 | • Group I: ablation of repetitive-regular activities followed by modified CPVI (mapping group; | 61% (25/41) AF termination in the mapping- guided ablation vs. 30% (12/40) with conventional strategy ( | • AF freedom after 1-year follow-up |
| Honarbakhsh et al., | 20 PsAF | • Driver domains identified by basket catheters | • 30 potential drivers: 19 showing rotational activity and 11 focal | N/A |
| Cochet et al., | PsAF = 41 | Driver domains identified using ECGi during AF | • Left atrial (LA)LGE imaging significantly associated with the number of re-entrant regions (R = 0.52; | AF freedom after 11 +/1 2 month-follow-up 25/34 (74%) pts. |
| Jais et al., | PAF = 100 | PVI + MI line vs. PVI + CTI line | PVI was achieved in all the pts, | 87% AF freedom without anti arrhythmic drugs after MI ablation after 1-year follow-up vs. 69 in the PVI group |
| Fassini et al., | • PAF = 126 | Randomization: 92 PVI vs. 95 PVI + MI line | MI block was achieved in 72% of the pts | AF freedom at 1-year follow-up: |
| Hocini et al., | • PAF = 90 | • PVI + roof line | Roof line blocked in 96% of the cases | 87% Af freedom after roof line after 15month-follow-up vs. 69% in the PVI group |
| Gaita et al., | • PAF = 125 | • 67 PVI alone (41 PAF + 26 PsAF) | • PVI was acutely achieved in all pts. | • AF freedom after a single procedure at 12-month follow-up, |
| Mun et al., | • PAF = 156 | • 52 = CPVI, | • CPVI = 100%, | • AF freedom after 15.6 ± 5 months of follow-up, |
| Kim et al., | • PAF = 100 | • 50 CPVI | • CPVI + CTI block = 100% | • AF freedom after 16.3 ± 4-month follow-up without AAD: |
| Kettering et al., | PsAF = 250 | • CPVI + roof line | • Roof blocked in all cases | • AF freedom after 1-year follow-up |
| Jadidi et al., | PsAF = 151 | • Group 1: 85: PVI + ablation at low-voltage areas (LVA < 0.5 mV in AF) with fractionated activity or rotational activity or discrete rapid local activity | • AF termination targeting LVAs with specific electrogram patterns = 73% | • Single- procedural AF-free survival after 13-month follow-up |
| Yamaguchi et al., | PsAF = 117 | • Group I: 101 = targeting low-voltage areas (<0.5 mV in SR) | • Complete low voltage areas elimination in 92% of the cases | • AF freedom after a single procedure after 18 ±7 months |
| BIFA trial | • PAF = 34 | • 92 PVI + box isolation of fibrotic area (BIFA) (<0.5 mV bipolar signals in sinus rhythm) | • Different stages of Fibrotic atrial cardiomyopathy (FACM) | • AF freedom after 16 ± 8 months |
| STABLE SR | PsAF = 229 pts | • STABLE-SR group: 114 = CPVI + CTI + ablation-homogenization of areas with low-voltage (LVZ 0.1–0.4 mV in SR) and complex electrograms | • AF termination in STABLER-SR group = 12.3% | AF-free survival after 18-month follow-up |
AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; CTI, cavo-tricuspid isthmus; EAM, electro-anatomical mapping; LVEF, left ventricular ejection fraction; CPVI, circumferential pulmonary veins isolation; MI, mitral isthmus; PAF, paroxysmal AF; PsAF, persistent AF; PVI, pulmonary veins isolation.